Although anti-Tim-3 alone is not enough to produce a therapeutic response, the combined application of anti-Tim-3 and anti-PD-1 antibodies can significantly improve the survival rate of a syngeneic mouse orthotopic glioma model [39]. Here, HAVCR2 is linked to central nervous system cancer.